AR037491A1 - Bromuro de (1alfa,2beta,4beta,5alfa,7beta,)-7-[(hidroxi-di-2tienil-acetil)oxi]-9,9-dimetil-3-oxa-9-azoniatriciclo.[3.3.1.0 /2,4]-nonano cristalino en la forma anhidra (bromuro de tiotropio cristalino anhidro) , un procedimiento para su preparacion , su utilizacion para la preparacion de un medicamen - Google Patents

Bromuro de (1alfa,2beta,4beta,5alfa,7beta,)-7-[(hidroxi-di-2tienil-acetil)oxi]-9,9-dimetil-3-oxa-9-azoniatriciclo.[3.3.1.0 /2,4]-nonano cristalino en la forma anhidra (bromuro de tiotropio cristalino anhidro) , un procedimiento para su preparacion , su utilizacion para la preparacion de un medicamen

Info

Publication number
AR037491A1
AR037491A1 ARP020102337A ARP020102337A AR037491A1 AR 037491 A1 AR037491 A1 AR 037491A1 AR P020102337 A ARP020102337 A AR P020102337A AR P020102337 A ARP020102337 A AR P020102337A AR 037491 A1 AR037491 A1 AR 037491A1
Authority
AR
Argentina
Prior art keywords
preparation
crystal
bromide
tiotropium bromide
oxa
Prior art date
Application number
ARP020102337A
Other languages
English (en)
Spanish (es)
Inventor
Sieger Peter Dr
Ulrike Werthmann
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of AR037491A1 publication Critical patent/AR037491A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C07D451/10—Oxygen atoms acylated by aliphatic or araliphatic carboxylic acids, e.g. atropine, scopolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pulmonology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
ARP020102337A 2001-06-22 2002-06-21 Bromuro de (1alfa,2beta,4beta,5alfa,7beta,)-7-[(hidroxi-di-2tienil-acetil)oxi]-9,9-dimetil-3-oxa-9-azoniatriciclo.[3.3.1.0 /2,4]-nonano cristalino en la forma anhidra (bromuro de tiotropio cristalino anhidro) , un procedimiento para su preparacion , su utilizacion para la preparacion de un medicamen AR037491A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10129710 2001-06-22
DE10215436 2002-04-08

Publications (1)

Publication Number Publication Date
AR037491A1 true AR037491A1 (es) 2004-11-17

Family

ID=26009556

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020102337A AR037491A1 (es) 2001-06-22 2002-06-21 Bromuro de (1alfa,2beta,4beta,5alfa,7beta,)-7-[(hidroxi-di-2tienil-acetil)oxi]-9,9-dimetil-3-oxa-9-azoniatriciclo.[3.3.1.0 /2,4]-nonano cristalino en la forma anhidra (bromuro de tiotropio cristalino anhidro) , un procedimiento para su preparacion , su utilizacion para la preparacion de un medicamen

Country Status (37)

Country Link
EP (1) EP1401445B1 (cg-RX-API-DMAC7.html)
JP (1) JP2005504015A (cg-RX-API-DMAC7.html)
KR (2) KR101011353B1 (cg-RX-API-DMAC7.html)
CN (1) CN100586948C (cg-RX-API-DMAC7.html)
AR (1) AR037491A1 (cg-RX-API-DMAC7.html)
AT (1) ATE337006T1 (cg-RX-API-DMAC7.html)
AU (1) AU2002345016B2 (cg-RX-API-DMAC7.html)
BG (1) BG66303B1 (cg-RX-API-DMAC7.html)
BR (1) BR0210537A (cg-RX-API-DMAC7.html)
CA (1) CA2450961C (cg-RX-API-DMAC7.html)
CO (1) CO5550423A2 (cg-RX-API-DMAC7.html)
CY (1) CY1105223T1 (cg-RX-API-DMAC7.html)
CZ (1) CZ302786B6 (cg-RX-API-DMAC7.html)
DE (1) DE50207943D1 (cg-RX-API-DMAC7.html)
DK (1) DK1401445T3 (cg-RX-API-DMAC7.html)
EA (1) EA005813B1 (cg-RX-API-DMAC7.html)
EE (1) EE05316B1 (cg-RX-API-DMAC7.html)
EG (1) EG24851A (cg-RX-API-DMAC7.html)
ES (1) ES2271280T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20031066B1 (cg-RX-API-DMAC7.html)
HU (1) HUP0400333A3 (cg-RX-API-DMAC7.html)
IL (2) IL159238A0 (cg-RX-API-DMAC7.html)
ME (1) ME00412B (cg-RX-API-DMAC7.html)
MX (1) MXPA03011718A (cg-RX-API-DMAC7.html)
MY (1) MY122779A (cg-RX-API-DMAC7.html)
NO (1) NO334301B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ530690A (cg-RX-API-DMAC7.html)
PE (2) PE20081305A1 (cg-RX-API-DMAC7.html)
PL (1) PL208137B1 (cg-RX-API-DMAC7.html)
PT (1) PT1401445E (cg-RX-API-DMAC7.html)
RS (1) RS50441B (cg-RX-API-DMAC7.html)
SA (1) SA02230255B1 (cg-RX-API-DMAC7.html)
SI (1) SI1401445T1 (cg-RX-API-DMAC7.html)
SK (1) SK287262B6 (cg-RX-API-DMAC7.html)
TW (2) TWI261589B (cg-RX-API-DMAC7.html)
UY (1) UY27342A1 (cg-RX-API-DMAC7.html)
WO (1) WO2003000265A1 (cg-RX-API-DMAC7.html)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10212264A1 (de) 2002-03-20 2003-10-02 Boehringer Ingelheim Pharma Kristallines Mikronisat, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels
US7056916B2 (en) 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
US20050038004A1 (en) * 2003-07-31 2005-02-17 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
WO2005042527A1 (de) * 2003-11-03 2005-05-12 Boehringer Ingelheim International Gmbh Neues kristallines anhydrat mit anticholinerger wirksamkeit
DE102004016179A1 (de) * 2004-03-30 2005-10-20 Boehringer Ingelheim Pharma Verbindungen zur Behandlung von proliferativen Prozessen
PT1781298E (pt) 2004-04-22 2012-02-03 Boehringer Ingelheim Int Combinações farmacêuticas contendo benzoxazinas para o tratamento de doenças respiratórias
DE102004024454A1 (de) 2004-05-14 2005-12-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Enantiomerenreine Betaagonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
US7220742B2 (en) 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
DE602004020337D1 (de) 2004-08-11 2009-05-14 Boehringer Ingelheim Pharma Anticholinergika enthaltende Arzneimittel zur Behandlung von Krankheiten der ableitenden Harnwege
US20060079544A1 (en) * 2004-08-13 2006-04-13 Boehringer Ingelheim International Gmbh Medicaments for the prevention or treatment of alveolar pneumonia comprising an anticholinergic
DE102004048389A1 (de) 2004-10-01 2006-04-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Modifizierung von Oberflächen von Laktose als Hilfsstoff zur Verwendung für Pulverinhalativa
WO2006111549A1 (de) 2005-04-21 2006-10-26 Boehringer Ingelheim International Gmbh Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen
EA013239B1 (ru) 2005-04-28 2010-04-30 Бёрингер Ингельхайм Интернациональ Гмбх Новые соединения для лечения воспалительных заболеваний
PL1881980T3 (pl) * 2005-05-02 2013-01-31 Boehringer Ingelheim Int Nowe krystaliczne formy bromku tiotropium
MX2007013691A (es) * 2005-05-02 2008-01-21 Boehringer Ingelheim Int Nuevas formas cristalinas de bromuro de tiotropio.
DE102005030733A1 (de) 2005-07-01 2007-01-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen enthaltend langwirksame Beta-2-Agonisten und wenigstens einen weiteren Wirkstoff
AU2006281449B2 (en) 2005-08-15 2013-01-31 Boehringer Ingelheim International Gmbh Method for producing betamimetics
TWI396541B (zh) 2005-10-10 2013-05-21 Boehringer Ingelheim Int 用於治療呼吸疾病之新穎藥物組合
US7423146B2 (en) 2005-11-09 2008-09-09 Boehringer Ingelheim International Gmbh Process for the manufacturing of pharmaceutically active 3,1-benzoxazine-2-ones
PT1869035E (pt) 2005-12-19 2013-01-10 Sicor Inc Novas formas de brometo de tiotrópio e processos para sua preparação
US9108962B2 (en) 2005-12-19 2015-08-18 Sicor, Inc. Forms of tiotropium bromide and processes for preparation thereof
CN100999521B (zh) * 2006-01-13 2010-12-08 江苏正大天晴药业股份有限公司 结晶性抗胆碱药噻托溴铵
EP1847543A1 (de) 2006-04-19 2007-10-24 Boehringer Ingelheim Pharma GmbH & Co. KG Dihydrothienopyrimidine zur Behandlung von entzündlichen Erkrankungen
DE502007006951D1 (de) 2006-08-07 2011-05-26 Boehringer Ingelheim Pharma Arzneimittelkombinationen zur behandlung von atemwegserkrankungen
PE20080610A1 (es) 2006-08-22 2008-07-15 Boehringer Ingelheim Int Nuevos beta-agonistas enantiomericamente puros, procedimientos para su preparacion y uso como medicamentos
GB0716026D0 (en) 2007-08-16 2007-09-26 Norton Healthcare Ltd An inhalable medicament
PT2215092E (pt) 2007-10-19 2012-04-10 Boehringer Ingelheim Int Piperidino-di-hidrotienopirimidinas substituídas
EP2093219A1 (de) 2008-02-22 2009-08-26 Boehringer Ingelheim International Gmbh Kristalline, enantiomerenreine Salzform eines Betamimetikums und dessen Verwendung als Arzneimittel
PE20120061A1 (es) 2008-12-19 2012-02-19 Boehringer Ingelheim Int Derivados de pirimidina como antagonistas del receptor ccr2
EP2403851B1 (en) 2009-03-06 2015-06-17 Mahmut Bilgic New crystalline forms of tiotropium bromide
JP5658272B2 (ja) 2009-12-17 2015-01-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ２の新規アンタゴニスト及びこれらの使用
WO2011073154A1 (en) 2009-12-17 2011-06-23 Boehringer Ingelheim International Gmbh New ccr2 receptor antagonists and uses thereof
KR20120125267A (ko) 2010-01-29 2012-11-14 베링거 인겔하임 인터내셔날 게엠베하 치환된 나프티리딘 및 ｓｙｋ 키나제 억제제로서의 이의 용도
WO2011141474A1 (en) 2010-05-12 2011-11-17 Boehringer Ingelheim International Gmbh Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
JP5646736B2 (ja) 2010-05-12 2014-12-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規ｃｃｒ２受容体アンタゴニスト、これらの製造方法、及び薬物としてのこれらの使用
US8841313B2 (en) 2010-05-17 2014-09-23 Boehringer Ingelheim International Gmbh CCR2 antagonists and uses thereof
US9018212B2 (en) 2010-05-25 2015-04-28 Boehringer Ingelheim International Gmbh Pyridazine carboxamides as CCR2 receptor antagonists
WO2011151251A1 (en) 2010-06-01 2011-12-08 Boehringer Ingelheim International Gmbh New ccr2 antagonists
TR201007108A2 (tr) * 2010-08-25 2012-03-21 B�Lg�� Mahmut Yeni tiotropyum bromür kristali ve üretim yöntemi.@
WO2012101013A1 (en) 2011-01-28 2012-08-02 Boehringer Ingelheim International Gmbh Substituted pyridinyl-pyrimidines and their use as medicaments
TR201101897A2 (tr) 2011-02-28 2012-09-21 Bi̇lgi̇ç Mahmut Tiotropyum bromür içeren kristal madde
TR201111589A2 (tr) * 2011-03-03 2012-09-21 Bi̇lgi̇ç Mahmut Tiotropyum bromür susuz kristal formu.
TR201102068A2 (tr) 2011-03-03 2012-09-21 Bi̇lgi̇ç Mahmut Tiotropyum bromür içeren kristal maddeler
EP2721025B1 (en) 2011-06-16 2015-11-25 Boehringer Ingelheim International Gmbh New selective ccr2 antagonists
WO2013010839A1 (en) 2011-07-15 2013-01-24 Boehringer Ingelheim International Gmbh Novel and selective ccr2 antagonists
CA2843022C (en) 2011-07-26 2019-09-24 Boehringer Ingelheim International Gmbh Substituted quinolines and their use as medicaments
US20130059866A1 (en) 2011-08-24 2013-03-07 Boehringer Ingelheim International Gmbh Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma
PT2782914T (pt) 2011-11-25 2018-11-16 Adverio Pharma Gmbh Processo para a preparação de 5-flúor-1h-pirazolopiridinas substituídas
CZ304368B6 (cs) 2011-11-28 2014-04-02 Zentiva, K.S. Směsný solvát tiotropium bromidu a způsob jeho přípravy
GB201200525D0 (en) 2011-12-19 2012-02-29 Teva Branded Pharmaceutical Prod R & D Inc An inhalable medicament
PT106142B (pt) * 2012-02-10 2014-07-18 Hovione Farmaci Ncia S A Processo para a preparação de brometo de tiotrópio
US9096579B2 (en) 2012-04-20 2015-08-04 Boehringer Ingelheim International Gmbh Amino-indolyl-substituted imidazolyl-pyrimidines and their use as medicaments
EP2897955B1 (en) * 2012-09-11 2019-11-06 Bilgic, Mahmut New tiotropium bromide crystalline form
ES2620758T3 (es) 2012-11-05 2017-06-29 Zentiva K.S. Estabilización de solvatos de tiotropio
CN104341412A (zh) * 2013-07-29 2015-02-11 天津金耀集团有限公司 一种无水噻托溴铵结晶的制备方法
HRP20191364T1 (hr) 2014-03-19 2019-11-01 Boehringer Ingelheim Int Sik-inhibitori tipa heteroarila
US10034866B2 (en) 2014-06-19 2018-07-31 Teva Branded Pharmaceutical Products R&D, Inc. Inhalable medicament comprising tiotropium
HRP20201343T1 (hr) 2014-10-21 2020-11-27 Ariad Pharmaceuticals, Inc. Kristalni oblici 5-kloro-n4-[-2-(dimetilfosforil)fenil]-n2-{2-metoksi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]pirimidin-2,4-diamina
WO2017138896A1 (en) * 2016-02-11 2017-08-17 Sima Patent Ve Lisanslama Hizmetleri Ltd. Şti Crystalline form of tiotropium bromide anhydrate

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3931041C2 (de) * 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
US5610163A (en) * 1989-09-16 1997-03-11 Boehringer Ingelheim Gmbh Esters of thienyl carboxylic acids and amino alcohols and their quaternization products
AU2002214996B2 (en) * 2000-10-12 2007-03-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Crystalline monohydrate, method for producing the same and the use thereof in the production of a medicament
DE10064816A1 (de) * 2000-12-22 2002-06-27 Boehringer Ingelheim Pharma Verfahren zur Herstellung eines Anticholinergikums

Also Published As

Publication number Publication date
CN100586948C (zh) 2010-02-03
BG66303B1 (bg) 2013-03-29
SK522004A3 (en) 2004-06-08
EA200301293A1 (ru) 2004-08-26
EA005813B1 (ru) 2005-06-30
IL159238A (en) 2010-04-15
PE20081305A1 (es) 2008-10-01
TWI261589B (en) 2006-09-11
AU2002345016B2 (en) 2008-04-17
HUP0400333A3 (en) 2012-10-29
HK1068540A1 (zh) 2005-04-29
CY1105223T1 (el) 2010-03-03
PL208137B1 (pl) 2011-03-31
EE200400029A (et) 2004-04-15
MEP62008A (en) 2011-05-10
DE50207943D1 (de) 2006-10-05
HUP0400333A2 (hu) 2004-12-28
JP2005504015A (ja) 2005-02-10
TW200617007A (en) 2006-06-01
CZ2004120A3 (cs) 2004-05-12
KR100971616B1 (ko) 2010-07-22
KR20040018285A (ko) 2004-03-02
ATE337006T1 (de) 2006-09-15
ES2271280T3 (es) 2007-04-16
DK1401445T3 (da) 2006-11-27
UY27342A1 (es) 2003-02-28
BG108440A (bg) 2004-08-31
CO5550423A2 (es) 2005-08-31
EP1401445A1 (de) 2004-03-31
SK287262B6 (sk) 2010-04-07
KR101011353B1 (ko) 2011-01-28
CN1520294A (zh) 2004-08-11
KR20090031638A (ko) 2009-03-26
EP1401445B1 (de) 2006-08-23
WO2003000265A1 (de) 2003-01-03
HRP20031066B1 (en) 2011-10-31
BR0210537A (pt) 2004-06-22
RS50441B (sr) 2010-03-02
PL364489A1 (en) 2004-12-13
EE05316B1 (et) 2010-08-16
SA02230255B1 (ar) 2006-10-31
SI1401445T1 (sl) 2007-02-28
MXPA03011718A (es) 2004-12-06
HRP20031066A2 (en) 2004-04-30
IL159238A0 (en) 2004-06-01
MY122779A (en) 2006-05-31
CA2450961A1 (en) 2003-01-03
NO334301B1 (no) 2014-02-03
NZ530690A (en) 2005-05-27
PT1401445E (pt) 2006-10-31
EG24851A (en) 2010-10-27
PE20030130A1 (es) 2003-04-02
NO20035696D0 (no) 2003-12-19
CZ302786B6 (cs) 2011-11-09
ME00412B (me) 2011-10-10
CA2450961C (en) 2010-03-30
YU99703A (sh) 2006-05-25

Similar Documents

Publication Publication Date Title
AR037491A1 (es) Bromuro de (1alfa,2beta,4beta,5alfa,7beta,)-7-[(hidroxi-di-2tienil-acetil)oxi]-9,9-dimetil-3-oxa-9-azoniatriciclo.[3.3.1.0 /2,4]-nonano cristalino en la forma anhidra (bromuro de tiotropio cristalino anhidro) , un procedimiento para su preparacion , su utilizacion para la preparacion de un medicamen
TW200745111A (en) New compounds
SE0200979D0 (sv) New compounds
DE60318193D1 (en) Phenethanolaminderivate
IL158589A (en) Carboxylic acid substituted oxazole derivatives, process for their manufacture, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for the treatment and prophylaxis of diseases which are modulated by ppar-alpha and -gamma activators
SG169233A1 (en) Pharmaceutical compositions comprising apomorphine for pulmonary inhalation
MEP36608A (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
EA200401005A1 (ru) Дозированные ингаляторы под давлением, содержащие растворы бета-2-агонистов
CA2474479A1 (en) Composition for inhalation
ATE381537T1 (de) Formanilid-derivative als beta2-adrenorezeptor- agonisten
MY129422A (en) Medicinal compounds
ATE365720T1 (de) Agonisten von beta-adrenorezeptoren
CO5550426A2 (es) Novedoso metodo terapeutico
YU35503A (sh) Nove kompozicije lekova bazirane na solima tiotropijuma i solima salmeterola
NO20063047L (no) Vandige ciclesonidsuspensjoner for forstoving
EA201270144A1 (ru) Комбинированная терапия при лечении диабета
SG166125A1 (en) New pyrimidine derivatives and their use in therapy as well as the use of pyrimidine derivatives in the manufacture of a medicament for prevention and/or treatment of alzheimeræs disease
SE0100569D0 (sv) New compounds
BR112015009504A2 (pt) inibidores de rock
ATE367387T1 (de) Verwendung von oxindolderivaten zur behandlung von mit demenz in zusammenhang stehenden krankheiten, alzheimer-krankheit und mit glycogensynthasekinase-3 assoziierten leiden
EA200600854A1 (ru) Новые соли тиотропия, способ их получения, а также содержащие их лекарственные композиции
SE0102440D0 (sv) New compound
BR0210473A (pt) Composição compreendendo um inibidor da pde-4 e antagonista do receptor-h1 e seus usos na produção de um medicamento para o tratamento de doenças respiratórias
BR0210224A (pt) Formas de dosagem projetada para ser engolida diretamente e apresentada como uma formulação em comprimido ou cápsula deglutìvel, e, processo para preparação de uma forma de dosagem
BRPI0409380A (pt) composições farmacêuticas

Legal Events

Date Code Title Description
FC Refusal